C-Peptide Levels in Latent Autoimmune Diabetes in Adults Treated With Linagliptin Versus Glimepiride: Exploratory Results From a 2-Year Double-Blind, Randomized, Controlled Study

Johansen, Odd Erik; Boehm, Bernhard O.; Grill, Valdemar; Torjesen, Peter A.; Bhattacharya, Subir; Patel, Sanjay; Wetzel, Kristiane; Woerle, Hans-Juergen

doi:10.2337/dc13-1523

Cited by 74 publications

(64 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, a one-year prospective study conducted in LADA patients demonstrated that a combined treatment of sitagliptin to these patients who receive insulin provides significant improvements in the parameters of islet function (Zhao et al, 2014). Similarly, another DPP4i, linagliptin, contributes to a progressive increase in c-peptide levels in patients with LADA during a 2-year study (Johansen et al, 2014). Table 3 Effect of DPP4 inhibition in autoimmune/inflammatory diseases.…”

Section: Dpp4/cd26 Inhibition On Autoimmune Diabetesmentioning

confidence: 99%

“…HbA1c reduction in T1DM patients (Ellis et al, 2011;Farngren et al, 2012) No treatment efficacy in T1DM/LADA patients (Garg et al, 2013;Hari Kumar et al, 2013;Zhao et al, 2014) β cell preservation in LADA patients (Johansen et al, 2014;Zhao et al, 2014) No effect of β cell preservation in T1DM/LADA patients (Griffin et al, 2014;Hari Kumar et al, 2013) β cell preservation in animal model (Conarello et al, 2003;Jelsing et al, 2012;Kim et al, 2012;Kim et al, 2008;Pospisilik et al, 2003;Suarez-Pinzon et al, 2009;Takeda et al, 2012;Tian et al, 2010) IBD Increased risk in T2DM patients Wang et al, 2019) Improved colitis in animal model (Ban et al, 2011;Salaga et al, 2017;Salaga et al, 2018)…”

Section: Effect Of Dpp4 Inhibition Referencementioning

confidence: 99%

See 1 more Smart Citation

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions

Shao

et al. 2020

Pharmacology & Therapeutics

154

129

View full text Add to dashboard Cite

Section: Dpp4/cd26 Inhibition On Autoimmune Diabetesmentioning

confidence: 99%

Section: Effect Of Dpp4 Inhibition Referencementioning

confidence: 99%

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions

Shao

et al. 2020

Pharmacology & Therapeutics

154

129

View full text Add to dashboard Cite

“…97 Use of DPP4 inhibitors in both Asian Chinese and Caucasians have shown to improve C-peptide levels. 96,102,103 However, more studies are needed to assess the long-term clinical effects.…”

Section: Similaritiesmentioning

confidence: 99%

Latent autoimmune diabetes in adults (LADA) in Asian and European populations

Kumar

Leiva

2017

Diabetes Metabolism Res

View full text Add to dashboard Cite

Diabetes mellitus is a chronic disorder caused by relative or absolute insulin deficiency and characterized by chronic hyperglycaemia. It is expected that by year 2025, 80% of all type 2 diabetic patients will be living in developing or low- and middle-income countries. Among Asians, there has been an overall increase in abdominal obesity; however, the risk of diabetes in these populations starts at much lower body mass index as compared to Caucasians. A significant proportion of diabetic patients with adult-onset, initially nonrequiring insulin treatment, have diabetes-associated autoantibodies in their sera. A new subclass of diabetes with the designation of latent autoimmune diabetes of adult-onset (LADA) has been proposed for this category of subjects. Studies have demonstrated that patients with autoimmune diabetes, characterized by the presence of glutamic decarboxylase autoantibodies display a different clinical phenotype from classical type 2 diabetes without glutamic decarboxylase autoantibodies. This subset of phenotypic type 2 diabetes subjects with islet autoantibodies tend to have sulphonylurea failure and need insulin treatment earlier in the disease process. Diagnosing LADA at an initial stage will be important so that insulin can be initiated earlier, facilitating improved glycemic control sooner as well as the preservation of residual beta-cell function in adult-onset autoimmune diabetes. Because of differences in dietary habits, environmental factors, and phenotypic characteristics between European and Asian populations, there may be heterogeneity in the prevalence and other characteristics of LADA in these two populations.

show abstract

“…Recently Johasen et al [28] found that another DPP-4 inhibitor, linagliptin, preserves β-cell function in persons with LADA during a 2-year study. However, the beneficial metabolic effect of DPP-4 inhibitors in addition to insulin therapycould occur independently of immune effects leading secondary to reduced β-cell stress, reduced glucagon, or β-cell regeneration.…”

Section: Discussionmentioning

confidence: 99%

Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes

Duvnjak

Blaslov

Lovrenčić

et al. 2016

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

C-Peptide Levels in Latent Autoimmune Diabetes in Adults Treated With Linagliptin Versus Glimepiride: Exploratory Results From a 2-Year Double-Blind, Randomized, Controlled Study

Cited by 74 publications

References 5 publications

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions

Latent autoimmune diabetes in adults (LADA) in Asian and European populations

Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes

Contact Info

Product

Resources

About